vs
布鲁克（BRKR）与帕可Bio（PACB）财务数据对比。点击上方公司名可切换其他公司
布鲁克的季度营收约是帕可Bio的21.9倍（$977.2M vs $44.6M）。布鲁克净利率更高（2.7% vs -90.4%，领先93.1%）。帕可Bio同比增速更快（13.8% vs -0.2%）。布鲁克自由现金流更多（$207.2M vs $-19.9M）。过去两年布鲁克的营收复合增速更高（16.4% vs 7.3%）
布鲁克公司是美国科学仪器制造商，总部位于马萨诸塞州比勒里卡，为公开上市企业。公司产品服务于分子与材料研究、工业及应用分析领域，旗下设有布鲁克科学仪器、布鲁克能源与超导技术（BEST）两大业务板块。
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
BRKR vs PACB — 直观对比
营收规模更大
BRKR
是对方的21.9倍
$44.6M
营收增速更快
PACB
高出14.1%
-0.2%
净利率更高
BRKR
高出93.1%
-90.4%
自由现金流更多
BRKR
多$227.1M
$-19.9M
两年增速更快
BRKR
近两年复合增速
7.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $977.2M | $44.6M |
| 净利润 | $26.0M | $-40.4M |
| 毛利率 | 46.0% | 37.1% |
| 营业利润率 | 7.8% | -92.3% |
| 净利率 | 2.7% | -90.4% |
| 营收同比 | -0.2% | 13.8% |
| 净利润同比 | 89.8% | -1802.7% |
| 每股收益（稀释后） | $0.10 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BRKRPACB
| Q4 25 | $977.2M | $44.6M | ||
| Q3 25 | $860.5M | $38.4M | ||
| Q2 25 | $797.4M | $39.8M | ||
| Q1 25 | $801.4M | $37.2M | ||
| Q4 24 | $979.6M | $39.2M | ||
| Q3 24 | $864.4M | $40.0M | ||
| Q2 24 | $800.7M | $36.0M | ||
| Q1 24 | $721.7M | $38.8M |
净利润BRKRPACB
| Q4 25 | $26.0M | $-40.4M | ||
| Q3 25 | $-59.6M | $-38.0M | ||
| Q2 25 | $7.6M | $-41.9M | ||
| Q1 25 | $17.4M | $-426.1M | ||
| Q4 24 | $13.7M | $2.4M | ||
| Q3 24 | $40.9M | $-60.7M | ||
| Q2 24 | $7.6M | $-173.3M | ||
| Q1 24 | $50.9M | $-78.2M |
毛利率BRKRPACB
| Q4 25 | 46.0% | 37.1% | ||
| Q3 25 | 44.1% | 41.4% | ||
| Q2 25 | 44.9% | 36.9% | ||
| Q1 25 | 48.8% | -3.7% | ||
| Q4 24 | 50.4% | 25.6% | ||
| Q3 24 | 48.4% | 25.0% | ||
| Q2 24 | 48.0% | 16.5% | ||
| Q1 24 | 48.9% | 29.1% |
营业利润率BRKRPACB
| Q4 25 | 7.8% | -92.3% | ||
| Q3 25 | -6.0% | -101.1% | ||
| Q2 25 | 1.5% | -112.8% | ||
| Q1 25 | 4.0% | -1154.5% | ||
| Q4 24 | 7.4% | -390.1% | ||
| Q3 24 | 7.9% | -160.3% | ||
| Q2 24 | 6.0% | -488.3% | ||
| Q1 24 | 9.0% | -209.6% |
净利率BRKRPACB
| Q4 25 | 2.7% | -90.4% | ||
| Q3 25 | -6.9% | -98.9% | ||
| Q2 25 | 1.0% | -105.4% | ||
| Q1 25 | 2.2% | -1146.8% | ||
| Q4 24 | 1.4% | 6.0% | ||
| Q3 24 | 4.7% | -151.9% | ||
| Q2 24 | 0.9% | -481.3% | ||
| Q1 24 | 7.1% | -201.4% |
每股收益（稀释后）BRKRPACB
| Q4 25 | $0.10 | $-0.11 | ||
| Q3 25 | $-0.41 | $-0.13 | ||
| Q2 25 | $0.05 | $-0.14 | ||
| Q1 25 | $0.11 | $-1.44 | ||
| Q4 24 | $0.09 | $-0.44 | ||
| Q3 24 | $0.27 | $-0.22 | ||
| Q2 24 | $0.05 | $-0.64 | ||
| Q1 24 | $0.35 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $298.8M | $279.5M |
| 总债务越低越好 | $1.9B | — |
| 股东权益账面价值 | $2.5B | $5.3M |
| 总资产 | $6.2B | $784.1M |
| 负债/权益比越低杠杆越低 | 0.76× | — |
8季度趋势，按日历期对齐
现金及短期投资BRKRPACB
| Q4 25 | $298.8M | $279.5M | ||
| Q3 25 | $293.1M | $298.7M | ||
| Q2 25 | $92.0M | $314.7M | ||
| Q1 25 | $184.2M | $343.1M | ||
| Q4 24 | $183.4M | $389.9M | ||
| Q3 24 | $148.1M | $471.1M | ||
| Q2 24 | $169.7M | $509.8M | ||
| Q1 24 | $340.1M | $561.9M |
总债务BRKRPACB
| Q4 25 | $1.9B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $1.4B | — |
股东权益BRKRPACB
| Q4 25 | $2.5B | $5.3M | ||
| Q3 25 | $2.4B | $36.1M | ||
| Q2 25 | $1.8B | $61.5M | ||
| Q1 25 | $1.8B | $91.6M | ||
| Q4 24 | $1.8B | $506.6M | ||
| Q3 24 | $1.8B | $453.1M | ||
| Q2 24 | $1.8B | $492.7M | ||
| Q1 24 | $1.4B | $649.0M |
总资产BRKRPACB
| Q4 25 | $6.2B | $784.1M | ||
| Q3 25 | $6.4B | $803.2M | ||
| Q2 25 | $6.3B | $825.5M | ||
| Q1 25 | $5.9B | $860.8M | ||
| Q4 24 | $5.8B | $1.3B | ||
| Q3 24 | $6.1B | $1.5B | ||
| Q2 24 | $5.9B | $1.5B | ||
| Q1 24 | $4.5B | $1.7B |
负债/权益比BRKRPACB
| Q4 25 | 0.76× | — | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 1.34× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 1.18× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 0.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.8M | $-19.1M |
| 自由现金流经营现金流 - 资本支出 | $207.2M | $-19.9M |
| 自由现金流率自由现金流/营收 | 21.2% | -44.6% |
| 资本支出强度资本支出/营收 | 2.3% | 1.9% |
| 现金转化率经营现金流/净利润 | 8.84× | — |
| 过去12个月自由现金流最近4个季度 | $43.3M | $-114.1M |
8季度趋势，按日历期对齐
经营现金流BRKRPACB
| Q4 25 | $229.8M | $-19.1M | ||
| Q3 25 | $-33.2M | $-18.7M | ||
| Q2 25 | $-127.5M | $-29.4M | ||
| Q1 25 | $65.0M | $-44.1M | ||
| Q4 24 | $190.0M | $-30.6M | ||
| Q3 24 | $38.4M | $-45.5M | ||
| Q2 24 | $1.1M | $-54.3M | ||
| Q1 24 | $21.8M | $-75.7M |
自由现金流BRKRPACB
| Q4 25 | $207.2M | $-19.9M | ||
| Q3 25 | $-54.1M | $-18.8M | ||
| Q2 25 | $-148.8M | $-29.9M | ||
| Q1 25 | $39.0M | $-45.4M | ||
| Q4 24 | $153.3M | $-32.3M | ||
| Q3 24 | $5.8M | $-46.3M | ||
| Q2 24 | $-23.5M | $-55.7M | ||
| Q1 24 | $400.0K | $-79.6M |
自由现金流率BRKRPACB
| Q4 25 | 21.2% | -44.6% | ||
| Q3 25 | -6.3% | -48.9% | ||
| Q2 25 | -18.7% | -75.3% | ||
| Q1 25 | 4.9% | -122.3% | ||
| Q4 24 | 15.6% | -82.3% | ||
| Q3 24 | 0.7% | -115.7% | ||
| Q2 24 | -2.9% | -154.8% | ||
| Q1 24 | 0.1% | -205.0% |
资本支出强度BRKRPACB
| Q4 25 | 2.3% | 1.9% | ||
| Q3 25 | 2.4% | 0.2% | ||
| Q2 25 | 2.7% | 1.4% | ||
| Q1 25 | 3.2% | 3.7% | ||
| Q4 24 | 3.7% | 4.1% | ||
| Q3 24 | 3.8% | 2.0% | ||
| Q2 24 | 3.1% | 4.1% | ||
| Q1 24 | 3.0% | 10.0% |
现金转化率BRKRPACB
| Q4 25 | 8.84× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -16.78× | — | ||
| Q1 25 | 3.74× | — | ||
| Q4 24 | 13.87× | -12.93× | ||
| Q3 24 | 0.94× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.43× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRKR
| Bsi Nano | $309.1M | 32% |
| Bsi Biospin | $267.0M | 27% |
| Other | $179.9M | 18% |
| Transferred Over Time | $142.5M | 15% |
| Energy And Supercon Technologies | $69.5M | 7% |
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
